Rates of discontinuation of first and second biologics
| First biologic | Second biologic | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Number of discontinuations (n) | Annual rate of discontinuation (95% CI) | Survival time (years) | N | Number of discontinuations (n) | Annual rate of discontinuation (95% CI) | Survival time (years) | |||||
| 25% | 50% | 75% | 25% | 50% | 75% | |||||||
| All biologics | 2281 | 1100 | 0.17 (0.16 to 0.18) | 1.08 | 4.08 | 10.42 | 1097 | 537 | 0.20 (0.18 to 0.22) | 1 | 3.33 | 9.92 |
| All biologics (onset <2005) | 1757 (77%) | 888 | 0.16 (0.15 to 0.18) | 1.25 | 4.33 | 10.50 | 577 (53%) | 301 | 0.16 (0.14 to 0.18) | 1.17 | 4.42 | 12 |
| All biologics (onset ≥2005) | 524 (23%) | 212 | 0.25 (0.22 to 0.29) | 0.67 | 3.08 | . | 520 (47%) | 236 | 0.31 (0.27 to 0.35) | 0.74 | 2.08 | . |
| TNF-inhibitors | 2225 (97.5%) | 1069 | 0.17 (0.16 to 0.18) | 1.17 | 4.08 | 10.42 | 988 (90%) | 481 | 0.19 (0.17 to 0.21) | 1 | 3.58 | 10.08 |
| Non-TNF inhibitors | 56 (2.5%) | 31 | 0.46 (0.33 to 0.66) | 0.66 | 1.66 | 3.32 | 109 (10%) | 56 | 0.38 (0.30 to 0.50) | 0.67 | 1.57 | 3.67 |
| Injectable biologics | 1352 (59%) | 611 | 0.16 (0.15 to 0.17) | 1.17 | 4.5 | . | 561 (51%) | 266 | 0.20 (0.18 to 0.22) | 1 | 3.17 | 12 |
| Infused biologics | 929 (41%) | 489 | 0.20 (0.18 to 0.21) | 1 | 3.33 | 8.75 | 536 (49%) | 271 | 0.20 (0.18 to 0.23) | 1 | 3.42 | 9.5 |
| Etanercept | 1018 (45%) | 467 | 0.15 (0.14 to 0.16) | 1.42 | 4.75 | . | 315 (29%) | 146 | 0.16 (0.14 to 0.19) | 1.42 | 4.58 | 12 |
| Infliximab | 873 (38%) | 458 | 0.19 (0.17 to 0.21) | 1.08 | 3.58 | 9 | 427 (39%) | 215 | 0.18 (0.16 to 0.20) | 1.08 | 4 | 10.08 |
| Adalimumab | 310 (14%) | 139 | 0.20 (0.17 to 0.23) | 0.83 | 3.58 | . | 218 (20%) | 112 | 0.26 (0.22 to 0.32) | 0.75 | 2.33 | 7.08 |
| Abatacept | 28 (1%) | 13 | 0.41 (0.24 to 0.70) | 0.5 | 1.5 | . | 61 (6%) | 31 | 0.37 (0.26 to 0.53) | 0.67 | 2.08 | 3.67 |
| Rituximab | 25 (1%) | 15 | 0.48 (0.29 to 0.79) | 0.66 | 1.74 | 3.32 | 42 (4%) | 24 | 0.40 (0.27 to 0.60) | 0.66 | 1.41 | . |
| Tocilizumab | 3 (0%) | 3 | 6 (1%) | 1 | ||||||||
| Certolizumab pegol | 16 (1%) | 3 | 17 (2%) | 5 | ||||||||
| Golimumab | 8 (0%) | 2 | 11 (1%) | 3 | ||||||||
TNF, tumour-necrosis factor.